GOBBI, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 119
AS - Asia 65
EU - Europa 64
AF - Africa 3
Totale 251
Nazione #
US - Stati Uniti d'America 119
SG - Singapore 33
CN - Cina 24
GB - Regno Unito 23
DE - Germania 9
IT - Italia 9
IN - India 6
FI - Finlandia 4
IE - Irlanda 3
RU - Federazione Russa 3
SE - Svezia 3
AT - Austria 2
EE - Estonia 2
FR - Francia 2
UA - Ucraina 2
BG - Bulgaria 1
CH - Svizzera 1
CI - Costa d'Avorio 1
ID - Indonesia 1
JO - Giordania 1
TG - Togo 1
ZA - Sudafrica 1
Totale 251
Città #
Singapore 25
Southend 23
Santa Clara 22
Fairfield 17
Woodbridge 15
Seattle 10
Houston 8
Wilmington 8
Ashburn 6
Boardman 6
Cambridge 6
Helsinki 4
Princeton 4
Ann Arbor 3
Dublin 3
Nanjing 3
Bologna 2
Mumbai 2
Shenyang 2
Turin 2
Westminster 2
Abidjan 1
Amman 1
Baoding 1
Beijing 1
Berlin 1
Chandler 1
Changsha 1
Chongqing 1
Fremont 1
Harbin 1
Hebei 1
Hefei 1
Jakarta 1
Krefeld 1
Lanzhou 1
Lausanne 1
Lomé 1
Milan 1
Nanchang 1
Nuremberg 1
Padova 1
Perugia 1
Shanghai 1
Sofia 1
Taiyuan 1
Vienna 1
Weifang 1
Wenzhou 1
Zhengzhou 1
Totale 202
Nome #
Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study 97
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 89
Chronic lymphocytic leukemia: prognostic factors and stage classification (author's transl) 28
B-b10 (Anti-CD25)-saporin immunotoxin—a possible tool in graft-versus-host disease treatment1 21
An epstein-barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins 14
Ber‐H2 (anti‐CD30)‐saporin immunotoxin: a new tool for the the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation 13
Totale 262
Categoria #
all - tutte 947
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 947


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202013 0 0 0 0 0 0 0 0 0 3 5 5
2020/202121 7 4 2 0 0 1 1 0 4 0 0 2
2021/202224 1 2 2 1 3 2 1 1 1 1 6 3
2022/202325 2 1 0 4 1 1 2 0 7 1 3 3
2023/202412 1 0 1 2 0 1 0 5 0 2 0 0
2024/202591 10 8 12 10 33 6 10 1 1 0 0 0
Totale 262